[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9300014A - Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion. - Google Patents

Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.

Info

Publication number
MX9300014A
MX9300014A MX9300014A MX9300014A MX9300014A MX 9300014 A MX9300014 A MX 9300014A MX 9300014 A MX9300014 A MX 9300014A MX 9300014 A MX9300014 A MX 9300014A MX 9300014 A MX9300014 A MX 9300014A
Authority
MX
Mexico
Prior art keywords
triaminobenzene
preparation
new derivatives
derivatives
acid addition
Prior art date
Application number
MX9300014A
Other languages
English (en)
Inventor
Hans Reinhold
Dieter Jurgen
Engel Bernhard Kutscher
Emmanuel Polymeropoulos
Stefan Szelenyi
Bernd Nickel
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of MX9300014A publication Critical patent/MX9300014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Derivados del 1,2,4-triaminobenceno farmacológicamente eficaces y sus sales de adición de ácidos farmacéuticamente compatibles.
MX9300014A 1992-01-08 1993-01-06 Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion. MX9300014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4200259A DE4200259A1 (de) 1992-01-08 1992-01-08 Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
MX9300014A true MX9300014A (es) 1993-07-01

Family

ID=6449201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300014A MX9300014A (es) 1992-01-08 1993-01-06 Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.

Country Status (13)

Country Link
US (1) US5384330A (es)
EP (1) EP0554543B1 (es)
JP (1) JP3145220B2 (es)
AT (1) ATE134611T1 (es)
CA (1) CA2086654C (es)
DE (3) DE4200259A1 (es)
DK (1) DK0554543T3 (es)
ES (1) ES2084914T3 (es)
GR (1) GR3019653T3 (es)
LU (1) LU91869I2 (es)
MX (1) MX9300014A (es)
SG (1) SG48046A1 (es)
ZA (1) ZA9311B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
HUP9903922A3 (en) 1996-06-27 2001-12-28 Smithkline Beecham Corp Il-8 receptor antagonists
BR9709952A (pt) * 1996-06-27 1999-08-10 Smithkline Beecham Corp Antagonistas de receptor de il-8
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
DE19752748A1 (de) 1997-11-28 1999-06-02 Bayer Ag Substituierte Phenyluracile
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6378671B1 (en) 2000-03-29 2002-04-30 Lord Corporation Magnetically actuated motion control device
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
DE10136046A1 (de) * 2001-07-25 2003-02-13 Viatris Gmbh Verfahren zur Herstellung von 1,2,4-Triaminobenzol-carbamidsäureestern
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
DK1578740T3 (da) * 2002-12-27 2007-07-30 Lundbeck & Co As H 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
KR20050089862A (ko) * 2002-12-27 2005-09-08 하. 룬트벡 아크티에 셀스카브 중추신경계 장애의 치료에 유용한 1,2,4-트리아미노벤젠유도체
MXPA05010000A (es) 2003-03-21 2005-11-17 Lundbeck & Co As H Derivados de p-diaminobenceno substituidos.
US20060264496A1 (en) * 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006092143A1 (en) 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
CN101163689A (zh) * 2005-04-22 2008-04-16 惠氏公司 {[(2r)-7-(2，6-二氯苯基)-5-氟-2，3-二氢-1-苯并呋喃-2-基]甲基}胺盐酸盐的晶形
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
CA2604916A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AR056979A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofuranos y usos de los mismos
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
NZ569517A (en) * 2006-02-07 2011-07-29 Lundbeck & Co As H Use of KCNQ-openers for threating or reducing the symptoms of schizophrenia
PA8720801A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
AU2007230997A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
PL2061465T3 (pl) * 2006-08-23 2014-03-31 Valeant Pharmaceuticals Int Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CA2670966A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
BRPI0916000A2 (pt) * 2008-07-18 2019-09-24 Valeant Pharmaceuticals Int formulação farmacêutica de liberação modificada, e, método para tratar um distúrbio
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
WO2011012659A2 (en) 2009-07-28 2011-02-03 Medichem S.A. Diethyl 4-(4-fluorobenzylamino)-1,2-phenylenedicarbamate, and salts thereof
WO2011039369A2 (en) 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
CA2787247A1 (en) 2010-01-20 2011-07-28 Glaxo Group Limited Novel composition
US20130131164A1 (en) 2010-02-19 2013-05-23 Medichem, S.A. Stabilized phenylcarbamate derivative in solid state
CN101921195A (zh) * 2010-08-02 2010-12-22 北京德众万全医药科技有限公司 一种瑞替加滨中间体的简单合成方法
WO2012098075A1 (en) * 2011-01-18 2012-07-26 Glaxo Group Limited Process for the preparation of retigabine
CN102241608A (zh) * 2011-05-12 2011-11-16 天津市汉康医药生物技术有限公司 瑞替加滨化合物及其组合物
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (zh) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
ITMI20120137A1 (it) * 2012-02-02 2013-08-03 Olon Spa Procedimento ed intermedi per la preparazione di retigabina
CN103373941B (zh) * 2012-04-11 2016-08-17 浙江九洲药物科技有限公司 瑞替加滨及其中间体的制备方法
EP2844639A4 (en) * 2012-04-30 2015-12-23 Scifluor Life Sciences Llc FLUORINATED DERIVATIVES OF 2-AMINO-4- (BENZYLAMINO) PHENYLCARBAMATE
WO2014023270A1 (en) 2012-08-09 2014-02-13 Zentiva, K.S. Salts or co-crystals of ethyl n-[2-amino-4-[(4-fluorophenyl)methylamino]-phenyl]carbamate
ITMI20121922A1 (it) 2012-11-12 2014-05-13 Dipharma Francis Srl Procedimento per la preparazione di un composto anticonvulsivante
CN103193657B (zh) * 2013-04-16 2015-08-05 石家庄度恩医药科技有限公司 一种合成依佐加滨中间体的方法
CN103664678B (zh) * 2013-11-06 2015-10-28 河北科技大学 一种n1-(4-氟苄基)-4-硝基苯基-1,3-二胺的中间体及其制备方法
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
WO2016077724A1 (en) * 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
CA3023340A1 (en) 2016-06-10 2017-12-14 Scifluor Life Sciences, Inc. Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
US11213517B2 (en) 2016-12-16 2022-01-04 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a T-type calcium channel blocker
US11369593B2 (en) 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity
KR20200063227A (ko) 2017-10-09 2020-06-04 라모트 앳 텔-아비브 유니버시티 리미티드 칼륨 이온 및 trpv1 채널의 조절제 및 이의 용도
US10676437B2 (en) 2017-12-13 2020-06-09 Scifluor Life Sciences, Inc. Fluorinated 4-(substituted amino)phenyl carbamate derivatives
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
WO2020157126A1 (en) 2019-01-29 2020-08-06 Università degli Studi di Salerno Modulators of potassium ion channels and uses thereof
BR112022010458A2 (pt) 2019-12-02 2022-09-06 Xenon Pharmaceuticals Inc Formulação pediátrica de liberação imediata do abridor de canais de potássio ezogabina
CA3214305A1 (en) * 2021-03-19 2022-09-22 Xyzagen, Inc. Prodrugs of kv7 channel openers
CA3239079A1 (en) 2021-11-19 2023-05-25 Icagen, Llc Novel heteroaryl-urea compounds as kv7.2 inhibitors
CN118265710A (zh) 2021-11-19 2024-06-28 伊卡根有限责任公司 吡啶化合物作为kv7.2增强剂
CN118510757A (zh) 2021-12-22 2024-08-16 伊卡根有限责任公司 环丙基化合物
CN116478068A (zh) 2022-01-14 2023-07-25 中国科学院上海药物研究所 一种高选择性kcnq4钾通道激动剂、其制备方法和用途
WO2023158584A1 (en) 2022-02-15 2023-08-24 Icagen, Llc New bicyclopentane derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
MC2029A1 (fr) * 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
DE3917113A1 (de) * 1989-05-26 1990-11-29 Schwarzkopf Gmbh Hans Verfahren zur selektiven herstellung von n(pfeil hoch)4(pfeil hoch)-substituierten 1,4-diamino-2-nitrobenzolen
GB8921792D0 (en) * 1989-09-27 1989-11-08 May & Baker Ltd New compositions of matter
US5220059A (en) * 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids

Also Published As

Publication number Publication date
EP0554543A2 (de) 1993-08-11
LU91869I2 (fr) 2011-11-14
CA2086654A1 (en) 1993-07-09
CA2086654C (en) 2003-09-23
ES2084914T3 (es) 1996-05-16
US5384330A (en) 1995-01-24
EP0554543A3 (en) 1993-10-27
JPH05345752A (ja) 1993-12-27
ZA9311B (en) 1993-08-05
GR3019653T3 (en) 1996-07-31
SG48046A1 (en) 1998-04-17
DE4200259A1 (de) 1993-07-15
EP0554543B1 (de) 1996-02-28
JP3145220B2 (ja) 2001-03-12
ATE134611T1 (de) 1996-03-15
DE59205496D1 (de) 1996-04-04
DE122011100044I1 (de) 2012-01-19
DK0554543T3 (da) 1996-03-18

Similar Documents

Publication Publication Date Title
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2175127T3 (es) Derivados de la quinazolina y su uso.
NO985711D0 (no) Farmas°ytikum for behandling av neurologiske og neuropsykiatriske mangler
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ES510348A0 (es) "procedimiento de preparacion de nuevos derivados 3,4-dihidro-5h-2,3-benzodiazepinos y de sus sales de adicion acidas farmaceuticamente aceptables".
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
ES2036259T3 (es) Un procedimientos para la preparacion de agentes antiinflamatorios.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
SE9300758D0 (sv) Process for the production of clavulanic acid
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
AR228586A1 (es) Procedimiento para preparar derivados de 2,3-dihidrobenzofuran-2-ona o croman-2-ona y sus sales farmaceuticamente aceptables
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
DE69104608D1 (de) Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
PT83253B (pt) Processo para a preparacao de p-acilaminobenzamidas
ES2032476T3 (es) Un procedimiento para preparar nuevos derivados de 2-anilinotiazolina.
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
SE9000948D0 (sv) New use
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.